Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00977938
Registration number
NCT00977938
Ethics application status
Date submitted
14/09/2009
Date registered
16/09/2009
Date last updated
9/06/2017
Titles & IDs
Public title
The Dual Antiplatelet Therapy Study (DAPT Study)
Query!
Scientific title
A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions
Query!
Secondary ID [1]
0
0
HCRIG080186
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Coronary Artery Disease
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Placebo comparator: 12m DAPT Study Arm - This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
Active comparator: 30m DAPT Study Arm - This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine treatment in addition to aspirin.
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT
Query!
Assessment method [1]
0
0
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure.
Query!
Timepoint [1]
0
0
18 months (12-30 months post-index procedure)
Query!
Primary outcome [2]
0
0
Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT
Query!
Assessment method [2]
0
0
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions.
Query!
Timepoint [2]
0
0
18 months (12-30 months post-index procedure)
Query!
Primary outcome [3]
0
0
GUSTO Severe or Moderate Bleeding - Randomized DES ITT
Query!
Assessment method [3]
0
0
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
Query!
Timepoint [3]
0
0
18 months (12-30 months post-index procedure)
Query!
Secondary outcome [1]
0
0
MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS
Query!
Assessment method [1]
0
0
Secondary powered endpoint
Query!
Timepoint [1]
0
0
33 months (0-33 months post-index procedure)
Query!
Secondary outcome [2]
0
0
Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS
Query!
Assessment method [2]
0
0
Secondary powered endpoint
Query!
Timepoint [2]
0
0
33 months (0-33 months post-index procedure)
Query!
Secondary outcome [3]
0
0
MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
21 months (12-33 months post-index procedure)
Query!
Secondary outcome [4]
0
0
Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT
Query!
Assessment method [4]
0
0
ST was assessed according to the Academic Research Consortium (ARC) definitions.
Query!
Timepoint [4]
0
0
21 months (12-33 months post-index procedure)
Query!
Secondary outcome [5]
0
0
GUSTO Severe or Moderate Bleeding - Randomized DES ITT
Query!
Assessment method [5]
0
0
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
Query!
Timepoint [5]
0
0
21 months (12-33 months post-index procedure)
Query!
Secondary outcome [6]
0
0
MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
18 months (12-30 months post-index procedure)
Query!
Secondary outcome [7]
0
0
Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT
Query!
Assessment method [7]
0
0
ST was assessed according to the Academic Research Consortium (ARC) definitions.
Query!
Timepoint [7]
0
0
18 months (12-30 months post-index procedure)
Query!
Secondary outcome [8]
0
0
GUSTO Severe or Moderate Bleeding - Randomized BMS ITT
Query!
Assessment method [8]
0
0
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
Query!
Timepoint [8]
0
0
18 months (12-30 months post-index procedure)
Query!
Secondary outcome [9]
0
0
MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
21 months (12-33 months post-index procedure)
Query!
Secondary outcome [10]
0
0
Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT
Query!
Assessment method [10]
0
0
ST was assessed according to the Academic Research Consortium (ARC) definitions.
Query!
Timepoint [10]
0
0
21 months (12-33 months post-index procedure)
Query!
Secondary outcome [11]
0
0
GUSTO Severe or Moderate Bleeding - Randomized BMS ITT
Query!
Assessment method [11]
0
0
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
Query!
Timepoint [11]
0
0
21 months (12-33 months post-index procedure)
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria (Enrollment):
1. Subject is > 18 years of age.
2. Subjects undergoing percutaneous intervention with stent deployment (or has w/in 24 hours).
3. Subjects without known contraindication to dual antiplatelet therapy for at least 30 months after enrollment and stent implantation.
4. The subject has consented to participate and has authorized the collection and release of his medical information by signing the "Patient Informed Consent Form". The informed consent will be valid for the duration of the trial or until the subject withdraws.
Inclusion Criterion (Randomization at 12 months):
1. Subject, at 12 months, is free from death, MI, stroke, repeat coronary revascularization, major bleeding, and stent thrombosis and has been compliant with dual antiplatelet therapy following stent implantation.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria (Enrollment):
1. Index procedure stent placement with stent diameter <2.25 mm or >4.0 mm.
2. Pregnant women.
3. Planned surgery necessitating discontinuation of antiplatelet therapy within the 30 months following enrollment.
4. Current medical condition with a life expectancy of less than 3 years.
5. Concurrent enrollment in another device or drug study whose protocol specifically excludes concurrent enrollment or that involves blinded placement of a DES or BMS other than those included as DAPT Study devices. The subject may only be enrolled in the DAPT Study once.
6. Subjects on warfarin or similar anticoagulant therapy.
7. Subjects with hypersensitivity or allergies to one of the drugs or components indicated in the Instructions for Use for the device implanted.
8. Subjects unable to give informed consent.
9. Subject treated with both DES and BMS during the index procedure.
Exclusion Criteria (Randomization at 12 months):
1. Pregnant women.
2. Subject switched thienopyridine type or dose within 6 months prior to randomization.
3. Percutaneous coronary intervention or cardiac surgery between 6 weeks post index procedure and randomization.
4. Planned surgery necessitating discontinuation of antiplatelet therapy within the 21 months following randomization.
5. Current medical condition with a life expectancy of less than 3 years.
6. Subjects on warfarin or similar anticoagulant therapy.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/06/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
25682
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
St. Vincents Hospital Sydney - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Prince of Wales Eastern Heart - Randwick
Query!
Recruitment hospital [3]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [4]
0
0
The Alfred Hospital - Prahran
Query!
Recruitment hospital [5]
0
0
Fremantle Hospital - Fremantle
Query!
Recruitment hospital [6]
0
0
The Mount Hospital - Nedlands
Query!
Recruitment hospital [7]
0
0
Royal Perth Hospital - Perth
Query!
Recruitment hospital [8]
0
0
Monash Heart - Clayton
Query!
Recruitment hospital [9]
0
0
St Vincents Hospital Melbourne - Fitzroy
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [3]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [4]
0
0
3004 - Prahran
Query!
Recruitment postcode(s) [5]
0
0
6160 - Fremantle
Query!
Recruitment postcode(s) [6]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [7]
0
0
6000 - Perth
Query!
Recruitment postcode(s) [8]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [9]
0
0
3065 - Fitzroy
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
District of Columbia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Florida
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Georgia
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Illinois
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Indiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Iowa
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Kentucky
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Louisiana
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Maine
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Maryland
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Massachusetts
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Michigan
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Minnesota
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Mississippi
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Missouri
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Nebraska
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
New Hampshire
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
New Jersey
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
New Mexico
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
New York
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
North Carolina
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
North Dakota
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Ohio
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Oklahoma
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Oregon
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Pennsylvania
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Rhode Island
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
South Carolina
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
South Dakota
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Tennessee
Query!
Country [37]
0
0
United States of America
Query!
State/province [37]
0
0
Texas
Query!
Country [38]
0
0
United States of America
Query!
State/province [38]
0
0
Utah
Query!
Country [39]
0
0
United States of America
Query!
State/province [39]
0
0
Virginia
Query!
Country [40]
0
0
United States of America
Query!
State/province [40]
0
0
Washington
Query!
Country [41]
0
0
United States of America
Query!
State/province [41]
0
0
Wisconsin
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Hradec Kralove
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Karlovy Vary
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Kromeriz
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Ostrava
Query!
Country [46]
0
0
Czechia
Query!
State/province [46]
0
0
Zlin
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
La Rochelle
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Lomme
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Nantes
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Nimes
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Paris
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Pessac
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Tourcoing
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
BE
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
SH
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Berlin
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Buxtehude
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Dresden
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Hamburg
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Leipzig
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Stade
Query!
Country [62]
0
0
Hungary
Query!
State/province [62]
0
0
Budapest
Query!
Country [63]
0
0
Hungary
Query!
State/province [63]
0
0
Nyiregyhaza
Query!
Country [64]
0
0
Hungary
Query!
State/province [64]
0
0
Pecs
Query!
Country [65]
0
0
Hungary
Query!
State/province [65]
0
0
Szeged
Query!
Country [66]
0
0
Hungary
Query!
State/province [66]
0
0
Zalaegerszeg
Query!
Country [67]
0
0
New Zealand
Query!
State/province [67]
0
0
Auckland
Query!
Country [68]
0
0
New Zealand
Query!
State/province [68]
0
0
Christchurch
Query!
Country [69]
0
0
New Zealand
Query!
State/province [69]
0
0
Hamilton
Query!
Country [70]
0
0
New Zealand
Query!
State/province [70]
0
0
Nelson
Query!
Country [71]
0
0
New Zealand
Query!
State/province [71]
0
0
Wellington
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Bialystok
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Bydgoszcz
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Krakow
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Szczecin
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Ustron
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Warszawa
Query!
Country [78]
0
0
Romania
Query!
State/province [78]
0
0
Bucuresti
Query!
Country [79]
0
0
Romania
Query!
State/province [79]
0
0
Cluj-Napoca
Query!
Country [80]
0
0
Romania
Query!
State/province [80]
0
0
Targu Mures
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Bucks
Query!
Country [82]
0
0
United Kingdom
Query!
State/province [82]
0
0
Cambs
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Devon
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
Dorset
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
Essex
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
Herts
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
N York
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Scotland
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Somerset
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Strath
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Chertsey
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Coventry
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Dundee
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Edinburgh
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Leicester
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
London
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Newcastle
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Plymouth
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Baim Institute for Clinical Research
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Abbott
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Commercial sector/industry
Query!
Name [2]
0
0
Boston Scientific Corporation
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Commercial sector/industry
Query!
Name [3]
0
0
Bristol-Myers Squibb
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Other collaborator category [4]
0
0
Commercial sector/industry
Query!
Name [4]
0
0
Sanofi-Synthelabo
Query!
Address [4]
0
0
Query!
Country [4]
0
0
Query!
Other collaborator category [5]
0
0
Commercial sector/industry
Query!
Name [5]
0
0
Cordis Corporation
Query!
Address [5]
0
0
Query!
Country [5]
0
0
Query!
Other collaborator category [6]
0
0
Commercial sector/industry
Query!
Name [6]
0
0
Eli Lilly and Company
Query!
Address [6]
0
0
Query!
Country [6]
0
0
Query!
Other collaborator category [7]
0
0
Commercial sector/industry
Query!
Name [7]
0
0
Daiichi Sankyo
Query!
Address [7]
0
0
Query!
Country [7]
0
0
Query!
Other collaborator category [8]
0
0
Commercial sector/industry
Query!
Name [8]
0
0
Medtronic
Query!
Address [8]
0
0
Query!
Country [8]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety and effectiveness of dual antiplatelet therapy to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents. Similar analysis will be conducted in a smaller cohort of bare metal coronary stent - treated subjects.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00977938
Query!
Trial related presentations / publications
Berg DD, Yeh RW, Mauri L, Morrow DA, Kereiakes DJ, Cutlip DE, Gao Q, Jarolim P, Michelson AD, Frelinger AL 3rd, Cange AL, Sabatine MS, O'Donoghue ML. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr;51(3):675-681. doi: 10.1007/s11239-020-02221-5. Stefanescu Schmidt AC, Steg PG, Yeh RW, Kereiakes DJ, Tanguay JF, Hsieh WH, Massaro JM, Mauri L, Cutlip DE; DAPT Investigators. Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study). Am J Cardiol. 2019 Dec 15;124(12):1813-1820. doi: 10.1016/j.amjcard.2019.09.006. Epub 2019 Sep 26. Berry NC, Kereiakes DJ, Yeh RW, Steg PG, Cutlip DE, Jacobs AK, Abbott JD, Hsieh WH, Massaro JM, Mauri L; DAPT Study Investigators. Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women. Circ Cardiovasc Interv. 2018 Aug;11(8):e005308. doi: 10.1161/CIRCINTERVENTIONS.117.005308. Yeh RW, Kereiakes DJ, Steg PG, Cutlip DE, Croce KJ, Massaro JM, Mauri L; DAPT Study Investigators. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2017 Oct 31;70(18):2213-2223. doi: 10.1016/j.jacc.2017.09.011. Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D'Agostino RB Sr, Massaro JM, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol. 2017 May 1;2(5):478-487. doi: 10.1001/jamacardio.2017.0063. Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, Yeh RW, D'Agostino RB Sr, Massaro JM, Hsieh WH, Mauri L; DAPT Investigators. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation. 2017 May 2;135(18):1720-1732. doi: 10.1161/CIRCULATIONAHA.116.024835. Epub 2017 Feb 22. Resor CD, Nathan A, Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Gabriel Steg P, Hsieh WH, Mauri L; Dual Antiplatelet Therapy Study Investigators. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. Circulation. 2016 Oct 4;134(14):989-998. doi: 10.1161/CIRCULATIONAHA.116.024531. Epub 2016 Aug 30. Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Steg PG, Wiviott SD, Mauri L; DAPT Study Investigators. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol. 2016 May 31;67(21):2492-502. doi: 10.1016/j.jacc.2016.03.485. Epub 2016 Apr 1. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775. Erratum In: JAMA. 2016 Jul 19;316(3):350. doi: 10.1001/jama.2016.6123. JAMA. 2016 Jul 19;316(3):350. doi: 10.1001/jama.2016.9558. Meredith IT, Tanguay JF, Kereiakes DJ, Cutlip DE, Yeh RW, Garratt KN, Lee DP, Steg PG, Weaver WD, Holmes DR Jr, Brindis RG, Trebacz J, Massaro JM, Hsieh WH, Mauri L; DAPT Study Investigators. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation. 2016 May 3;133(18):1772-82. doi: 10.1161/CIRCULATIONAHA.115.016783. Epub 2016 Mar 18. Erratum In: Circulation. 2016 May 31;133(22):e671. doi: 10.1161/CIR.0000000000000430. Hermiller JB, Krucoff MW, Kereiakes DJ, Windecker S, Steg PG, Yeh RW, Cohen DJ, Cutlip DE, Massaro JM, Hsieh WH, Mauri L; DAPT Study Investigators. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. JACC Cardiovasc Interv. 2016 Jan 25;9(2):138-47. doi: 10.1016/j.jcin.2015.10.001. Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, Wiviott SD, Cohen DJ, Massaro JM, D'Agostino RB Sr, Braunwald E, Kereiakes DJ; DAPT Study Investigators. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J. 2016 Jan 21;37(4):378-85. doi: 10.1093/eurheartj/ehv614. Epub 2015 Nov 18. Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; DAPT Study Investigators. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. JACC Cardiovasc Interv. 2015 Oct;8(12):1552-62. doi: 10.1016/j.jcin.2015.05.026. Erratum In: JACC Cardiovasc Interv. 2015 Dec 21;8(14):1913. Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE, Cohen DJ, Tanguay JF, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L; DAPT Study Investigators. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015 May 26;65(20):2211-21. doi: 10.1016/j.jacc.2015.03.003. Epub 2015 Mar 15. Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA. 2015 Mar 17;313(11):1113-21. doi: 10.1001/jama.2015.1671. Erratum In: JAMA. 2015 Jun 2;313(21):2185. doi: 10.1001/jama.2015.4806. JAMA. 2016 Jul 5;316(1):105. doi: 10.1001/jama.2016.8640. JAMA. 2016 Jul 5;316(1):105. doi: 10.1001/jama.2016.8646. Yeh RW, Czarny MJ, Normand SL, Kereiakes DJ, Holmes DR Jr, Brindis RG, Weaver WD, Rumsfeld JS, Roe MT, Kim S, Driscoll-Shempp P, Mauri L. Evaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2015 Jan;8(1):96-102. doi: 10.1161/CIRCOUTCOMES.114.001239. Epub 2014 Nov 16. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 4;371(23):2155-66. doi: 10.1056/NEJMoa1409312. Epub 2014 Nov 16. Matteau A, Yeh RW, Kereiakes D, Orav EJ, Massaro J, Steg PG, Normand SL, Cutlip DE, Mauri L. Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study). Am J Cardiol. 2014 Apr 1;113(7):1146-52. doi: 10.1016/j.amjcard.2013.10.015. Epub 2013 Nov 8. Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR, Bangalore S, Cutlip DE, Pencina M, Massaro JM. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010 Dec;160(6):1035-41, 1041.e1. doi: 10.1016/j.ahj.2010.07.038.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Laura Mauri, MD, MSc
Query!
Address
0
0
Brigham and Women's Hospital
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00977938
Download to PDF